Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 59729-32-7] Citalopram hydrobromide

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B1287
Brand:	MCE
CAS:	59729-32-7

Overview

MDL	MFCD02101306
Molecular Weight	405.30
Molecular Formula	C20H22BrFN2O
SMILES	N#CC1=CC2=C(C(C3=CC=C(F)C=C3)(CCCN(C)C)OC2)C=C1.[H]Br

For research use only. We do not sell to patients.

5 Publications Citing Use of MCE

[1]Neurochem Int. 2019 Dec;131:104552.
[2]Eur J Pharmacol. 2018 Sep 27;841:57-66.
[3]J Clin Psychopharmacol. 2021 Jun 11.
[4]Pharmacol Res Perspect. 2020 Apr;8(2):e00575.
[5]Research Square Preprint. 2021 Feb.

Summary

Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) . Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC ₅₀ of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC ₅₀ of 14 nM. Antidepressant effect ^[1] .

In Vitro

Citalopram（25-150 μM) shows a concentration-dependent cytotoxicity on the viability of rat B104, human SH-SY5Y, IMR32 and Kelly neuroblastoma cell lines and human primary Schwann cells (HSC) ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	Rat B104, human SH-SY5Y, IMR32 and Kelly neuroblastoma cells
Concentration:	50, 100, 125, 150 μM for B104 cells 25, 50, 100, 125 μM for SH-SY5Y cells 25, 50, 100, 125, 150 μM for Kelly cells 25, 50, 100, 125 μM for IMR32 cells 50, 100, 125, 150 μM for HSCs
Incubation Time:	24 h ours
Result:	Significantly decreased B104 cell viability, 61%, 33% and 11% at respectively 100, 125 and 150 μM in B104 cell line. Drastically decreased SH-SY5Y cell viability, 17%, 1% at respectively 100 and 125 μM in SH-SY5Y cell line. Significantly decreased Kelly cell viability, 64%, 9% and 0% at respectively 100, 125 and 150 μM in Kelly cell line. Drastically decreased IMR32 cell viability, 36%, 1% and 0% at respectively 50, 100 and 125 μM in IMR32 cell line.

In Vivo

Acute administration of Citalopram (1-10 mg/kg, i.p. 1 h before an elevated plus-maze test) to Spontaneously Hypertensive rats (SHRs), Lewis (LEW) rats, and Wistar-Kyoto (WKY) rats, i.e., rat strains differing for their emotionality, promotes anxiety, and/or hypoactivity, except in WKY rats. In the three strains, such a pretreatment increased central 5-HT levels and/or decreased 5-hydroxyindoleacetic acid levels ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male rats from the SHR, LEW, and WKY strains, aged 6–8 weeks ^[3]
Dosage:	1, 3.3, or 10 mg/kg
Administration:	Injected i.p.
Result:	Increased significantly 5-HT in SHRs and WKY rats, and decreased 5-HIAA in all strains, in either a dose-dependent (LEW and WKY rats) or a dose-independent (SHRs) manner.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00249886	Sunnybrook Health Sciences Centre	Major Depression	September 2002	Phase 3
NCT01149980	Dr. Reddy´s Laboratories Limited	Healthy	October 2003	Phase 1
NCT04145076	King´s College London	Autism Spectrum Disorder	December 15, 2014	Not Applicable
NCT02269540	Centre for Addiction and Mental Health	Major Depressive Disorder	October 2014	Early Phase 1
NCT03511118	Duke University\|The Emmes Company, LLC\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Lactating Women on Select DOI\|Breastfed Infants of Mothers on Select DOI	October 4, 2018
NCT04097288	University Hospital Bispebjerg and Frederiksberg	Stress Urinary Incontinence\|Fecal Incontinence	September 17, 2019	Phase 1
NCT01937182	University of Aarhus\|Danish Council for Independent Research\|The Danish Regions Medicine Foundation	Stroke, Ischemic	September 2013	Phase 2
NCT00477165	Stanford University	Irritable Bowel Syndrome	April 2001	Phase 2
NCT00208572	Walter Reed Army Medical Center\|The Defense and Veterans Brain Injury Center\|VA Palo Alto Health Care System\|Hunter Holmes McGuire VA Medical Center\|United States Naval Medical Center, San Diego\|59th Medical Wing\|James A. Haley Veterans Administration Hospital	Traumatic Brain Injury	November 2003	Not Applicable
NCT01153165	Liam Heaney\|Asthma UK\|Belfast Health and Social Care Trust	Asthma	November 2010	Not Applicable
NCT00249405	University of Cincinnati\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Alcoholism\|Alcohol Abuse	February 2005	Phase 2
NCT01951053	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Healthy	January 2010	Phase 1
NCT01575158	University of Aarhus\|Danish University Antidepressant Group	Depression	October 1997	Not Applicable
NCT01367756	Hoffmann-La Roche	Healthy Volunteer	May 2011	Phase 1
NCT00896441	Stanford University	Depression\|Mood Disorders\|Depressive Disorder	February 2009	Not Applicable
NCT00086645	Boston University\|National Institute of Mental Health (NIMH)	Autistic Disorder	April 2004	Phase 2
NCT01179568	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)\|American Foundation for Suicide Prevention	Complicated Grief\|Bereavement	March 2010	Phase 2
NCT01099592	Centre hospitalier de l´Université de Montréal (CHUM)\|Canadian Institutes of Health Research (CIHR)\|Centre de Recherche du Centre Hospitalier de l´Université de Montréal\|Montreal Heart Institute	Acute Coronary Syndrome\|Major Depressive Episode	November 2010	Phase 4
NCT03779789	Azienda Ospedaliera Universitaria Integrata Verona\|University of Catania	Major Depressive Disorder	February 1, 2019	Phase 4
NCT02320240	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Depression\|Acute Kidney Injury	June 2013
NCT05346445	Hospital Regional 1o de Octubre\|Universidad Nacional Autonoma de Mexico\|National Polytechnic Institute, Mexico	Postmenopause\|Hot Flashes	January 20, 2021	Not Applicable
NCT00977353	China Medical University Hospital\|National Science Council, Taiwan	Major Depressive Disorder\|Depression\|Major Depression	April 2009	Phase 2
NCT00865943	Actavis Inc.	Healthy	July 2003	Phase 1
NCT01300364	Fundació Sant Joan de Déu\|Centro de Investigación Biomédica en Red de Salud Mental	Schizophrenia	November 2008	Phase 4
NCT00939835	Torrent Pharmaceuticals Limited	Healthy		Phase 1
NCT00018902	University of Pittsburgh\|National Institute of Mental Health (NIMH)	Depression	January 2001	Phase 2\|Phase 3
NCT01557946	Mclean Hospital	MDD\|Citalopram\|Major Depressive Disorder	March 2012	Phase 4
NCT03499171	Universitaire Ziekenhuizen KU Leuven	GERD	May 27, 2019	Phase 4
NCT02330068	Mayo Clinic	Major Depressive Disorder, Bipolar I and Bipolar II	December 2014
NCT04497168	University of Michigan\|National Institute on Aging (NIA)	Parkinson Disease	April 1, 2021	Phase 2
NCT00217828	University of Pittsburgh\|National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Heart Diseases	March 2002	Not Applicable
NCT01946607	University of Oxford\|Medical Research Council Cognition and Brain Sciences Unit	Antidepressive Agents, Second-Generation	July 2009	Not Applicable
NCT04846829	University of California, Los Angeles	Major Depressive Disorder	April 24, 2017	Early Phase 1
NCT03607331	China Academy of Chinese Medical Sciences	Depression\|Depressive Symptom\|Depressive Disorder	September 17, 2018	Early Phase 1
NCT00317746	Marina Klein\|Ontario HIV Treatment Network\|Schering-Plough\|CIHR Canadian HIV Trials Network\|McGill University Health Centre+Research Institute of the McGill University Health Centre	Depression\|HIV Infections\|Hepatitis C	November 2006	Phase 3
NCT03516604	University of Oxford\|Medical Research Council\|Pfizer	Depression, Unipolar	May 16, 2018	Phase 1
NCT01658228	New York State Psychiatric Institute\|National Institute on Aging (NIA)	Depression\|Mild Cognitive Impairment	September 2011	Phase 4
NCT00898807	JHSPH Center for Clinical Trials\|National Institute on Aging (NIA)\|National Institute of Mental Health (NIMH)	Alzheimer´s Disease\|Agitation	July 2009	Phase 3
NCT02237937	HolsboerMaschmeyer NeuroChemie GmbH\|Max-Planck-Institute of Psychiatry	Major Depression	September 2011	Phase 4
NCT02655354	University of Washington\|National Institutes of Health (NIH)\|National Institute of Mental Health (NIMH)\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Posttraumatic Stress Disorder\|Depression\|Alcohol-Related Disorders\|Suicidal Ideation\|Substance-Related Disorders\|Mild Cognitive Impairment\|Quality of Life\|Pain\|Wounds and Injury\|Brain Injuries\|Chronic Disease	October 2015	Not Applicable
NCT00067301	National Center for Complementary and Integrative Health (NCCIH)	Major Depression	September 2003	Phase 3
NCT00009204	Bruce Pollock\|National Institute of Mental Health (NIMH)\|University of Pittsburgh	Dementia\|Alzheimer Disease\|Dementia, Vascular	September 1995	Phase 3
NCT03278938	New York State Psychiatric Institute	Depressive Illness	June 29, 2012	Phase 4
NCT01254305	Forest Laboratories	Major Depressive Disorder	April 2011	Phase 2
NCT01041274	NYU Langone Health\|National Institute of Mental Health (NIMH)	Schizophrenia\|Schizophreniform Disorder	January 2010	Phase 4
NCT02386475	Hospital de Granollers	Stroke	January 2015	Phase 4
NCT01764867	Shanghai Mental Health Center	Major Depressive Disorder	June 2012	Phase 4
NCT02022709	Shanghai Mental Health Center\|Shanghai Municipal Science and Technology Commission\|Shanghai Jiao Tong University School of Medicine	Obsessive-Compulsive Disorder\|Anxiety Disorders\|Mental Disorders	January 2014	Phase 4
NCT00838305	California Pacific Medical Center Research Institute	MDMA Mechanism of Action	February 2009	Not Applicable
NCT01978782	Radboud University Medical Center	HIV\|Depression	January 2014	Phase 1
NCT02473250	New York State Psychiatric Institute	Bipolar Disorder	January 2015	Phase 4
NCT01601912	Vrije Universiteit Brussel	Whiplash Injuries	February 2013
NCT01568684	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Depressive Disorder\|Depressive Disorder, Major\|Depression	March 12, 2012	Phase 1
NCT00226694	University of Cincinnati\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Alcoholism\|Stress\|Alcohol Dependence	September 2003	Not Applicable
NCT00073658	University of Pittsburgh\|National Institute of Mental Health (NIMH)	Dementia	January 2000	Phase 2
NCT00865085	Actavis Inc.	Healthy	June 2003	Phase 1
NCT00047450	Veterans Medical Research Foundation\|National Institute of Mental Health (NIMH)	Schizophrenia	September 2001	Not Applicable
NCT00666757	Eli Lilly and Company\|Boehringer Ingelheim	Depression	May 2008	Phase 4
NCT02179268	Guiyang Medical University	Bone Mineral Density Quantitative Trait Locus 7	March 2012	Phase 3
NCT03282110	China Academy of Chinese Medical Sciences	Depression; Psychoneurotic\|Pain	November 30, 2017	Early Phase 1
NCT00271596	University of Iowa\|National Institute of Neurological Disorders and Stroke (NINDS)\|Cure Huntington´s Disease Initiative (CHDI)\|University of Rochester\|Mayo Clinic	Huntington Disease\|Chorea\|Executive Dysfunction	November 2005	Phase 2
NCT01216449	Rotman Research Institute at Baycrest\|Centre for Addiction and Mental Health\|University of Toronto	Healthy Young and Elderly Volunteers	April 2009	Not Applicable
NCT03538691	Otsuka Pharmaceutical Development & Commercialization, Inc.	Major Depressive Disorder	July 13, 2018	Phase 3
NCT05271084	Hawler Medical University	Major Depressive Disorder	November 10, 2021	Phase 1\|Phase 2
NCT04776226	Ege University	Stroke Recurrence\|Cardiovascular Events\|Depression	February 11, 2017	Not Applicable
NCT00218036	The University of Texas Health Science Center, Houston\|National Institute on Drug Abuse (NIDA)\|University of Texas	Cocaine Abuse\|Opiate Dependence	July 2006	Phase 2
NCT00297505	National Institute on Drug Abuse (NIDA)	Cocaine Dependence	April 2001	Phase 2
NCT00834834	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Borderline Personality Disorder\|Suicide	March 2009	Phase 4
NCT01473381	Forest Laboratories	Major Depressive Disorder	December 2011	Phase 4
NCT00893256	National Institute of Mental Health and Neuro Sciences, India	Schizophrenia\|Negative Symptoms	December 2004	Phase 4
NCT00254020	Sunnybrook Health Sciences Centre	Depression	June 2005	Phase 4
NCT00021528	National Institute of Mental Health (NIMH)	Depression	July 2001	Phase 4
NCT00955474	Massachusetts General Hospital	Major Depressive Disorder With Psychotic Features	September 2008	Phase 4
NCT01154647	Vrije Universiteit Brussel\|Research Foundation Flanders\|Universiteit Antwerpen\|University Hospital, Antwerp\|Artesis University College, Antwerp	Fatigue Syndrome, Chronic\|Fibromyalgia\|Arthritis, Rheumatoid	September 2010	Not Applicable
NCT01189812	Columbia Northwest Pharmaceuticals	Major Depressive Disorder\|Dysthymia\|Depression Not Otherwise Specified\|Borderline Personality Disorder	March 2010	Phase 2
NCT00993876	Zentrum für Integrative Psychiatrie\|German Research Foundation	Cognitive Performance in Major Depression	August 2005	Not Applicable
NCT05041582	Chih-Wei Tang\|Taipei Veterans General Hospital, Taiwan\|University of Oxford\|Far Eastern Memorial Hospital	Stroke\|Motor	September 1, 2021	Phase 3
NCT00254007	Sunnybrook Health Sciences Centre\|Ontario Mental Health Foundation	Depression\|Traumatic Brain Injury	July 2003	Phase 4
NCT00692445	Targacept Inc.	Major Depressive Disorder\|Depression	June 2008	Phase 2
NCT00562861	Tufts Medical Center\|National Institute of Mental Health (NIMH)	Bipolar Disorder\|Bipolar Depression	November 2007	Phase 2\|Phase 3
NCT01725048	UNC Lineberger Comprehensive Cancer Center	Major Depressive Disorder\|Neoplasms	January 2011	Early Phase 1
NCT03899285	Ciusss de L´Est de l´�le de Montréal	Major Depressive Disorder	January 8, 2018	Phase 2
NCT01149967	Dr. Reddy´s Laboratories Limited	Healthy	October 2003	Phase 1
NCT02092974	Charite University, Berlin, Germany	Healthy Young and Older Adults	April 2014	Phase 1
NCT00108563	US Department of Veterans Affairs\|VA Office of Research and Development	Hepatitis C\|Depression	October 2003	Phase 4
NCT01896349	Hospital de Clinicas de Porto Alegre	Treatment Resistant Depression	April 2013	Not Applicable
NCT00162916	Ontario Neurotrauma Foundation	Depression	May 2005	Phase 4
NCT00048815	Massachusetts General Hospital\|National Institute of Mental Health (NIMH)\|National Center for Complementary and Integrative Health (NCCIH)\|Office of Dietary Supplements (ODS)	Depression	February 2003	Not Applicable
NCT02374567	Hannover Medical School	Dementia\|Depression\|Schizophrenia\|Psychosomatic Disorders\|Anxiety Disorders	January 2015	Phase 3
NCT00376051	Sunnybrook Health Sciences Centre\|Alzheimer Society of Canada	Frontotemporal Dementia	September 2006	Phase 4
NCT02000726	University of Michigan	Depression	July 2013	Phase 2
NCT02113943	Institut National de la Santé Et de la Recherche Médicale, France	Normal Volunteers	April 2014	Phase 2
NCT00351910	AstraZeneca	Major Depressive Disorder	May 2006	Phase 3
NCT01919216	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Major Depressive Disorder	January 2010	Phase 4
NCT01424384	GlaxoSmithKline	Depressive Disorder and Anxiety Disorders	September 19, 2008	Phase 1
NCT00825825	Michael Henry, MD\|Forest Laboratories\|Steward St. Elizabeth´s Medical Center of Boston, Inc.	Antidepressant Activity in Healthy Volunteers	May 2007	Phase 4
NCT01778686	Gitte Moos Knudsen\|Rigshospitalet, Denmark	Healthy	January 2013	Not Applicable
NCT00015548	National Institute of Mental Health (NIMH)	Alzheimer´s Disease	March 2001	Not Applicable
NCT00269334	National Health Research Institutes, Taiwan\|National Science Council, Taiwan\|Taipei Medical University WanFang Hospital\|Chang Gung Memorial Hospital\|Jing-Ho Mental Hospital, Taiwan\|Tsyr-Huey Mental Hospital	Major Depression	December 2005	Phase 4
NCT00188396	University Health Network, Toronto\|Ontario Mental Health Foundation	Major Depressive Disorder\|Depression	April 2004	Not Applicable
NCT03907215	Idorsia Pharmaceuticals Ltd.	Healthy	April 9, 2019	Phase 1
NCT01436643	Novartis Pharmaceuticals\|Novartis	Depression\|Relapsing-remitting Multiple Sclerosis	November 2011	Phase 4
NCT04161209	University of Oxford\|University of Bath	Depression\|Depressive Disorder\|Mental Disorder\|Antidepressive Agents\|Cognition\|Stress	October 11, 2019	Not Applicable
NCT04766229	University College Dublin\|Irish Cancer Society\|Big Health Inc.	Menopause\|Cancer\|Insomnia	June 21, 2021	Phase 2
NCT03746691	Universitaire Ziekenhuizen KU Leuven	Gastro Esophageal Reflux	February 1, 2017	Phase 4
NCT00613470	Mayo Clinic\|National Institute of General Medical Sciences (NIGMS)\|National Center for Research Resources (NCRR)	Depression	March 2005	Phase 1
NCT04355455	Universitaire Ziekenhuizen KU Leuven	Gastroesophageal Reflux	July 2011	Not Applicable
NCT01535573	Joy Schmitz\|National Institute on Drug Abuse (NIDA)\|The University of Texas Health Science Center, Houston	Cocaine Dependence	December 2010	Phase 2
NCT00532519	Hadassah Medical Organization	Prurigo Nodularis		Not Applicable
NCT02080832	Virginia Commonwealth University\|The University of Texas Health Science Center, Houston\|National Institute on Drug Abuse (NIDA)	Cocaine Dependence	February 2010	Phase 2
NCT00794040	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Mood Disorder\|Mental Disorder Diagnosed in Childhood\|Attention Deficit and Disruptive Behavior Disorder\|Attention Deficit Hyperactivity Disorder	November 17, 2008	Phase 2
NCT03854578	Boehringer Ingelheim	Depressive Disorder, Major	March 12, 2019	Phase 1
NCT00538889	Wyeth is now a wholly owned subsidiary of Pfizer	Healthy	August 2007	Phase 1
NCT04590612	Western University, Canada	Parkinson Disease\|Depression	January 2021	Not Applicable
NCT00962039	John V. Campo, M.D.\|National Institute of Mental Health (NIMH)\|Nationwide Children´s Hospital	Abdominal Pain\|Anxiety	July 2004	Phase 2\|Phase 3
NCT00221494	Mark Frye\|University of California, Los Angeles\|Mayo Clinic	Depression	January 2004	Phase 4
NCT00363909	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Breast Cancer\|Hot Flashes\|Psychosocial Effects of Cancer and Its Treatment	November 2006	Phase 3
NCT02028026	Massachusetts General Hospital	Major Depressive Disorder\|Anxiety\|Comorbidity	April 2013	Phase 4
NCT00864890	Actavis Inc.	Healthy	June 2003	Phase 1
NCT00774813	Kalaco Scientific, Inc.	Depression	October 2007	Phase 2
NCT00930293	University of Pittsburgh\|National Institute of Mental Health (NIMH)	Depression\|Anxiety	July 2009	Not Applicable
NCT01657760	VA Office of Research and Development	Alcohol Dependence	May 1, 2014	Phase 1
NCT01742832	University of Chicago	Major Depressive Disorder	May 2013	Phase 2
NCT02893371	University of New Mexico\|Patient-Centered Outcomes Research Institute\|Montana State University\|National Alliance on Mental Illness Montana\|CGStat LLC\|Risk Benefit Statistics LLC\|National Alliance on Mental Illness New Mexico\|National Alliance on Mental Illness Westside Los Angeles	Bipolar Disorder	September 2016
NCT00433121	Sykehuset Innlandet HF\|Demensforbundet, Norway	Dementia	September 2006	Phase 4
NCT00150527	Queen´s University\|H. Lundbeck A+S	Healthy	September 2005
NCT00609531	University of North Carolina, Chapel Hill\|National Institute of Mental Health (NIMH)	Autism Spectrum Disorders	January 2007	Phase 1
NCT02825342	Evangelismos Hospital	Chest Pain Rule Out Myocardial Infarction	March 2014	Phase 4
NCT00080158	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Depression\|Suicide, Attempted	March 2004	Phase 2\|Phase 3
NCT02711215	Medical University of Vienna	Major Depressive Disorder	May 2015	Phase 4
NCT05063604	Hospital Universitari de Bellvitge\|Institut Català d´Oncologia	Breast Cancer\|Major Depressive Episode	May 10, 2022	Phase 2
NCT01312922	PharmaNeuroBoost N.V.	Major Depressive Disorder	September 2011	Phase 3
NCT00047671	National Institute of Mental Health (NIMH)	Depression	June 2002	Phase 4
NCT00667121	Mayo Clinic\|National Cancer Institute (NCI)	Breast Cancer\|Depression\|Hot Flashes\|Psychosocial Effects of Cancer and Its Treatment	March 16, 2011
NCT04975724	Fidia Farmaceutici s.p.a.	Major Depressive Disorder	April 18, 2019	Phase 4
NCT04777838	University of Coimbra\|Instituto de Investigación Biomédica de Salamanca	Muscle Type Temporomandibular Disorders\|Myofascial Pain of the Masticatory Muscles	March 2021	Phase 2\|Phase 3
NCT00672659	PharmaNeuroBoost N.V.	Depression	February 2008	Phase 2
NCT01667744	Henry Ford Health System	Acute Coronary Syndrome	January 2018	Phase 1\|Phase 2
NCT01716221	University of Colorado, Denver	Friedreich Ataxia	October 2012	Phase 4
NCT00602290	University of California, Los Angeles\|National Institute of Mental Health (NIMH)	Depression	February 2008	Phase 4
NCT04169230	University of Oxford\|University of Bath	Molecular Mechanisms of Pharmacological Action\|Depression\|Depressive Disorder\|Mental Disorder\|Antidepressive Agents\|Cognition	October 11, 2019	Not Applicable
NCT00044798	University of Iowa\|National Institute of Mental Health (NIMH)	Depressive Disorder\|Depression	September 2001	Phase 3
NCT00594269	Sykehuset Innlandet HF\|Ullevaal University Hospital\|Eikertun Nursing Home\|University of Bergen\|Innlandet Hospital Trust, Sanderud\|Innlandet Hospital Trust, Reinsvoll\|Diakonhjemmet Hospital\|Sykehuset Telemark\|The Nordmøre and Romsdal Hospital Trust\|Songdalstunet Nursing Home\|Sykehuset Buskerud HF\|Kroken Nursing Home, Tromsø\|Kløveråsen, Bodø\|Bjørgene Omsorgssenter, Haugesund\|Alesund Hospital	Dementia	August 2008	Phase 4
NCT00369746	New York State Psychiatric Institute\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Major Depressive Disorder\|Alcohol Use Disorder	September 2006
NCT01032083	Imperial College London\|University of Manchester\|University of Southampton\|King´s College London\|University of Oxford\|University College, London\|University of Bristol	Schizophrenia	July 2011	Phase 4
NCT00876226	University of Nebraska	Short Bowel Syndrome	May 2010	Not Applicable
NCT00940238	Torrent Pharmaceuticals Limited	Healthy		Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 38 mg/mL ( 93.76 mM )

H ₂ O : 10 mg/mL ( 24.67 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4673 mL	12.3365 mL	24.6731 mL
5 mM	0.4935 mL	2.4673 mL	4.9346 mL
10 mM	0.2467 mL	1.2337 mL	2.4673 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 110 mg/mL (271.40 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.17 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] J Hyttel. Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):277-95.
[2] Laurent Sakka, et al. Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation. Oncotarget. 2017 Jun 27;8(26):42789-42807.
[3] F Pollier, et al. Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality. Neuropsychopharmacology. 2000 Jan;22(1):64-76.

Synonyms

5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, hydrobromide (1:1)

5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, monohydrobromide

Citalopram hydrobromide

Seropram

Cipramil

Celexa

Cipram

Lupram

Apertia

Sepram

Lu 10-171B

Elopram

Prisdal

(±)-Citalopram hydrobromide

Lecital

S-Pram

Pramcit

Cheer

Citopram

[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-isobenzofuran-5-carbonitrile hydrobromide

1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile hydrobromide

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart